abrocitinib
Selected indexed studies
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. (Health Technol Assess, 2024) [PMID:38343072]
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. (N Engl J Med, 2021) [PMID:33761207]
- Abrocitinib. (, 2006) [PMID:37247355]
_Worker-drafted node — pending editorial review._
Connections
abrocitinib is a side effect of
Sources
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. (2024) pubmed
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. (2021) pubmed
- Abrocitinib. (2006) pubmed
- Abrocitinib. (2012) pubmed
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (2020) pubmed
- Abrocitinib for the treatment of atopic dermatitis. (2023) pubmed
- Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. (2022) pubmed
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (2020) pubmed
- Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. (2022) pubmed
- Abrocitinib: First Approval. (2021) pubmed